If You Invested in Prestige Consumer Healthcare Inc. (PBH)
Looking for the current price? See the PBH quote & overviewWhat $1,000 or $10,000 in PBH Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Nov 4, 2015 |
|---|---|---|---|---|
| $1,000 | $818 -18% | $807 -19% | $1,067 +7% | $1,008 +1% |
| $10,000 | $8,178 -18% | $8,067 -19% | $10,670 +7% | $10,081 +1% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-03. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for PBH$1,000 Investment Over Time
PBH vs S&P 500Year-by-Year Returns
PBH annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2015Nov 4, 2015 to Dec 31, 2015 | $49.14 | $51.48 | +4.8% | +4.8% |
| 2016 | $51.48 | $52.10 | +1.2% | +6.0% |
| 2017 | $52.10 | $44.41 | -14.8% | -9.6% |
| 2018 | $44.41 | $30.88 | -30.5% | -37.2% |
| 2019 | $30.88 | $40.50 | +31.2% | -17.6% |
| 2020 | $40.50 | $34.87 | -13.9% | -29.0% |
| 2021 | $34.87 | $60.65 | +73.9% | +23.4% |
| 2022 | $60.65 | $62.60 | +3.2% | +27.4% |
| 2023 | $62.60 | $61.22 | -2.2% | +24.6% |
| 2024 | $61.22 | $78.09 | +27.6% | +58.9% |
| 2025 | $78.09 | $61.69 | -21.0% | +25.5% |
| 2026Dec 31, 2025 to Nov 3, 2026 | $61.69 | $49.54 | -19.7% | +0.8% |
About Prestige Consumer Healthcare Inc.
Healthcare · NYSE
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a consumer healthcare products company that markets, sells, manufactures and distributes branded over-the-counter (OTC) items. According to the company’s public disclosures, Prestige focuses on consumer healthcare products sold through retail outlets in the U.S. and Canada, Australia, and certain other international markets. Its business centers on established OTC brands across multiple everyday health categories.
The company is associated with the Pharmaceutical Preparation Manufacturing industry within the broader manufacturing sector. Prestige describes itself as a consumer healthcare products company rather than a prescription drug developer, emphasizing OTC products that are used for common health and personal care needs.
Brand portfolio and key categories
Prestige Consumer Healthcare reports a diverse portfolio of brands across women’s health, pain relief, eye and ear care, oral care, motion sickness, gastrointestinal care, pediatric OTC, diaper rash, lice treatment, earwax removal, antacids, rehydration, and nasal and sinus care. The company repeatedly highlights the following brands in its investor and news communications:
- Women’s health: Monistat® and Summer’s Eve® women’s health products.
- Pain relief: BC® and Goody's® pain relievers.
- Eye care: Clear Eyes® and TheraTears® eye care products.
- Specialty oral care: DenTek® specialty oral care products.
- Motion sickness: Dramamine® motion sickness treatments.
- GI and rectal care: Fleet® enemas and glycerin suppositories.
- Cough, cold and sore throat: Chloraseptic® and Luden's® sore throat treatments and drops.
- Dermatological care: Compound W® wart treatments.
- Pediatric OTC: Little Remedies® pediatric over-the-counter products.
- Diaper rash: Boudreaux’s Butt Paste® diaper rash ointments.
- Lice treatment: Nix® lice treatment.
- Ear care: Debrox® earwax remover.
- Antacid (Canada): Gaviscon® antacid in Canada.
- Rehydration and nasal care (Australia): Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia.
These brands position Prestige in multiple OTC segments rather than concentrating on a single therapeutic area. The company’s public commentary also references category performance such as gastrointestinal, women’s health, cough and cold, and eye and ear care.
Geographic focus and segments
Prestige Consumer Healthcare reports activity primarily in North America and selected international markets. In its earnings releases, the company discusses two reporting segments:
- North American OTC Healthcare: This segment includes OTC healthcare products sold in the U.S. and Canada. The company’s disclosures indicate that this segment covers categories such as gastrointestinal, women’s health, cough and cold, and eye and ear care, with brands including Summer’s Eve, Dramamine, Fleet and Clear Eyes mentioned in connection with segment performance.
- International OTC Healthcare: This segment covers markets outside North America, with company commentary highlighting growth in Australia and the role of brands such as Hydralyte® and the Fess® nasal and sinus care line.
Prestige states that it has sales throughout the U.S. and Canada, Australia, and certain other international markets, reflecting a footprint that extends beyond a single country but remains focused on OTC consumer health products.
Business activities and operations
In its news releases, Prestige Consumer Healthcare states that it markets, sells, manufactures and distributes its consumer healthcare products to retail outlets. This indicates that the company is involved in multiple parts of the value chain for its OTC brands, including production and distribution, rather than acting solely as a marketing organization.
The company also discloses that one of its subsidiaries, Medtech Products Inc., is responsible for certain branded products such as Little Remedies® Honey Cough Syrup. Medtech issued a voluntary nationwide recall of specific lots of Little Remedies Honey Cough Syrup due to microbial contamination and loss of shelf stability, underscoring that product quality and regulatory compliance are important aspects of Prestige’s operations.
Financial reporting and public company status
Prestige Consumer Healthcare Inc. files periodic reports and current reports with the U.S. Securities and Exchange Commission (SEC). The company trades on the New York Stock Exchange under the symbol PBH and issues quarterly and annual earnings releases that discuss revenues, net income, earnings per share, free cash flow, leverage, and segment performance. The company also provides non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share, and free cash flow, and reconciles these to GAAP metrics in its earnings materials.
Recent SEC Form 8-K filings describe the release of quarterly financial results and the use of investor presentations. Another Form 8-K details a definitive agreement by a Prestige subsidiary to acquire Pillar5 Pharma Inc., a sterile ophthalmic manufacturer and current Clear Eyes® supplier, subject to specified closing conditions. This transaction is described as part of a long-term strategy to expand eye care production capacity.
Risk, regulation and product stewardship
Prestige’s public disclosures reference factors that can affect its performance, including business and economic conditions, consumer trends, advertising and marketing effectiveness, foreign exchange, competitive pressures, and the ability of its manufacturing operations and third-party manufacturers and logistics providers to meet demand and manage costs. The company also notes the role of tariffs, labor shortages, inflation and geopolitical conditions in its forward-looking statements.
The voluntary recall of certain lots of Little Remedies Honey Cough Syrup by Medtech Products Inc., a Prestige company, illustrates the regulatory environment in which the company operates. The recall was conducted with the knowledge of the U.S. Food and Drug Administration and included guidance for consumers on potential health effects and how to seek refunds or report adverse events.
Investor communications and events
Prestige Consumer Healthcare regularly announces the timing of its quarterly earnings releases and related conference calls. The company also participates in investor conferences, such as consumer staples and consumer growth and e-commerce conferences, and makes slide presentations available via webcasts. These activities are described in its press releases and SEC Form 8-K filings, which also note that investor presentations are intended to be considered in the context of the company’s SEC filings and other public announcements.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Prestige Consumer Healthcare Inc. investment returns
How much would $1,000 invested in Prestige Consumer Healthcare Inc. be worth today?
If you invested $1,000 in Prestige Consumer Healthcare Inc. (PBH) 10 years ago on 2016-11-03, your investment would be worth $1,067 as of 2026-11-03, a +6.7% price return without dividends, growing at a compounded rate of 0.7% per year (CAGR).
Has Prestige Consumer Healthcare Inc. outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare PBH performance over available time periods.
What is Prestige Consumer Healthcare Inc.'s average annual return?
The compound annual growth rate (CAGR) of PBH’s share price over the past 10 years is 0.7%, without dividends. Individual years vary a great deal, and PBH’s best recent full year was 2021 (+73.9%) while the worst was 2018 (-30.5%).
For informational and educational purposes only, not investment advice.